Cargando…
Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank
Hypertension appears to be one of the commonest comorbidities in COVID-19 patients, although whether hypertensive individuals have a higher risk of severe COVID-19 compared with non-hypertensives is unclear. It is also unclear whether the absolute level of systolic blood pressure, or the type of ant...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645600/ https://www.ncbi.nlm.nih.gov/pubmed/36350810 http://dx.doi.org/10.1371/journal.pone.0276781 |
_version_ | 1784826996427063296 |
---|---|
author | Pavey, Holly Kulkarni, Spoorthy Wood, Angela Ben-Shlomo, Yoav Sever, Peter McEniery, Carmel Wilkinson, Ian |
author_facet | Pavey, Holly Kulkarni, Spoorthy Wood, Angela Ben-Shlomo, Yoav Sever, Peter McEniery, Carmel Wilkinson, Ian |
author_sort | Pavey, Holly |
collection | PubMed |
description | Hypertension appears to be one of the commonest comorbidities in COVID-19 patients, although whether hypertensive individuals have a higher risk of severe COVID-19 compared with non-hypertensives is unclear. It is also unclear whether the absolute level of systolic blood pressure, or the type of anti-hypertensive medication is related to this risk. Analyses were conducted using data from the UK Biobank and linked health records. Logistic regression models were fitted to assess the impact of hypertension, systolic blood pressure (SBP) and medications on the risk of severe COVID-19. 16,134 individuals tested positive for severe acute respiratory syndrome-coronavirus, 22% (n = 3,584) developed severe COVID-19 and 40% (n = 6,517) were hypertensive. Hypertension was associated with 22% higher odds of severe COVID-19 (Odds ratio (OR) 1.22; 95% confidence interval (CI) 1.12, 1.33), compared with normotension after adjusting for confounding variables. In those taking anti-hypertensive medications, elevated SBP showed a dose-response relationship with severe COVID-19 (150-159mmHg versus 120-129mmHg (OR 1.91; 95% CI 1.44, 2.53), >180+mmHg versus 120-129mmHg (OR 1.93; 95% CI 1.06, 3.51)). SBP <120mmHg was associated with greater odds of severe COVID-19 (OR 1.40; 95% CI 1.11, 1.78). Angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers were not associated with altered risk of severe COVID-19. Hypertension is an important risk factor for COVID-19. A better understanding of the underlying mechanisms is warranted in case of more severe strains or other viruses in the future. |
format | Online Article Text |
id | pubmed-9645600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-96456002022-11-15 Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank Pavey, Holly Kulkarni, Spoorthy Wood, Angela Ben-Shlomo, Yoav Sever, Peter McEniery, Carmel Wilkinson, Ian PLoS One Research Article Hypertension appears to be one of the commonest comorbidities in COVID-19 patients, although whether hypertensive individuals have a higher risk of severe COVID-19 compared with non-hypertensives is unclear. It is also unclear whether the absolute level of systolic blood pressure, or the type of anti-hypertensive medication is related to this risk. Analyses were conducted using data from the UK Biobank and linked health records. Logistic regression models were fitted to assess the impact of hypertension, systolic blood pressure (SBP) and medications on the risk of severe COVID-19. 16,134 individuals tested positive for severe acute respiratory syndrome-coronavirus, 22% (n = 3,584) developed severe COVID-19 and 40% (n = 6,517) were hypertensive. Hypertension was associated with 22% higher odds of severe COVID-19 (Odds ratio (OR) 1.22; 95% confidence interval (CI) 1.12, 1.33), compared with normotension after adjusting for confounding variables. In those taking anti-hypertensive medications, elevated SBP showed a dose-response relationship with severe COVID-19 (150-159mmHg versus 120-129mmHg (OR 1.91; 95% CI 1.44, 2.53), >180+mmHg versus 120-129mmHg (OR 1.93; 95% CI 1.06, 3.51)). SBP <120mmHg was associated with greater odds of severe COVID-19 (OR 1.40; 95% CI 1.11, 1.78). Angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers were not associated with altered risk of severe COVID-19. Hypertension is an important risk factor for COVID-19. A better understanding of the underlying mechanisms is warranted in case of more severe strains or other viruses in the future. Public Library of Science 2022-11-09 /pmc/articles/PMC9645600/ /pubmed/36350810 http://dx.doi.org/10.1371/journal.pone.0276781 Text en © 2022 Pavey et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Pavey, Holly Kulkarni, Spoorthy Wood, Angela Ben-Shlomo, Yoav Sever, Peter McEniery, Carmel Wilkinson, Ian Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank |
title | Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank |
title_full | Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank |
title_fullStr | Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank |
title_full_unstemmed | Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank |
title_short | Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank |
title_sort | primary hypertension, anti-hypertensive medications and the risk of severe covid-19 in uk biobank |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645600/ https://www.ncbi.nlm.nih.gov/pubmed/36350810 http://dx.doi.org/10.1371/journal.pone.0276781 |
work_keys_str_mv | AT paveyholly primaryhypertensionantihypertensivemedicationsandtheriskofseverecovid19inukbiobank AT kulkarnispoorthy primaryhypertensionantihypertensivemedicationsandtheriskofseverecovid19inukbiobank AT woodangela primaryhypertensionantihypertensivemedicationsandtheriskofseverecovid19inukbiobank AT benshlomoyoav primaryhypertensionantihypertensivemedicationsandtheriskofseverecovid19inukbiobank AT severpeter primaryhypertensionantihypertensivemedicationsandtheriskofseverecovid19inukbiobank AT mcenierycarmel primaryhypertensionantihypertensivemedicationsandtheriskofseverecovid19inukbiobank AT wilkinsonian primaryhypertensionantihypertensivemedicationsandtheriskofseverecovid19inukbiobank |